

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

078883/0120

SERIAL NO.

09/533,798-10/774,176

INFORMATION DISCLOSURE CITATION

APPLICANT

Miles William CARROLL et al.

FILING DATE

3/24/2000

GROUP ART UNIT

1643-1644

Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	5,118,672	06/92	Schinz et al.	514	47	

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
						YES	NO
A2	99/15684	04/99	WIPO				
A3	99/15683	04/99	WIPO				
A4	89/07947	09/89	WIPO				
A5	92/03568	03/92	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

A6	Guschlbauer et al., "Poly-2'-deoxy-2'-fluoro-cytidylic acid: enzymatic synthesis, spectroscopic characterization and interaction with poly-inosinic acid" 1977 Nucleic Acids Res. 4:1933
A7	Schibahara et al., "Site-directed cleavage of RNA" 1987 Nucleic Acids Res. 15:4403
A8	Gershon et al., "The nucleotide sequence around the capripoxvirus thymidine kinase gene reveals a gene shared specifically with leporipoxvirus" J. Gen. Virol. 70:525, 1989
A9	Weir et al., "Nucleotide sequence of the vaccinia virus thymidine kinase gene and the nature of spontaneous frameshift mutations" J. Virol. 46:530, 1983
A10	Esposito et al., "Nucleotide sequence of the thymidine kinase gene region of monkeypox and variola viruses" Virology 135:561, 1984
A11	Kilpatrick et al., "Cloning and physical mapping of yada monkey tumor virus DNA" Virology 143:399, 1985
A12	Binns et al., "Comparison of a conserved region in fowlpox virus and vaccinia virus genomes and the translocation of the fowlpox virus thymidine kinase gene" J. Gen. Virol. 69:1275, 1988
A13	Schnitzlein et al., "A rapid method for identifying the thymidine kinase genes of avipoxviruses" J. Virological Method 20:341, 1988
A14	Fathi et al., "Efficient targeted insertion of an unselected marker into the vaccinia virus genome" Virology 97:105, 1986

EXAMINER

Marianne DiBriano

DATE CONSIDERED

7/10/07

- * EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PT 00449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

078883/0120

SERIAL NO.

09/533,798

MAY 13 2004

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT

Miles William CARROLL et al.

FILING DATE

3/24/2000

GROUP ART UNIT

1643

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

A15

Graham et al., "A new technique for the assay of infectivity of human adenovirus 5 DNA" Virol. 52, 456-467, 1973

A16

Stralinger et al., "Liposomes as carriers for intracellular delivery of nucleic acids" Methods in Enzymology, 101: 512-527 1983

A17

Studier et al., "Use of T7 RNA polymerase to direct expression of cloned genes" Methods in Enzymol. 185: 60-89, 1990

A18

Matthias et al., "Eukaryotic expression vectors for the analysis of mutant proteins" 1989 NAR 17, 6418

A19

Wootton & Federhen, "Statistics of local complexity in amino acid sequences and sequence database" 1993, Computers and Chemistry 17:149-163

A20

Myers et al., "Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein" 1994 J. Biol. Chem 169:9319-9324

A21

Starzynska et al., "Prognostic significance of 5T4 oncofetal antigen expression in colorectal" Br. J. Cancer 1994 May; 69(5):899-902

A22

Starzynska et al., "The expression of 5T4 antigen in colorectal and gastric carcinoma" Br. J. Cancer 1992 Nov; 66(5):867-869

A23

Hobbs et al., "polynucleotides containing 2'-amino-2'-deoxyribose and 2'-azido-2'-deoxyribose" 1973 Biochemistry 12:5138

A24

Starzynska et al., "5T4 oncofetal antigen in gastric carcinoma and its clinical significance" Eur J. Gastroenterol Hepatol 1998 Jun; 10(6):479-484

A25

Carsberg et al., "Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells" 1996, Int J Cancer Sep 27; 68(1):84-92

A26

Yewdell et al., "TAP-independent delivery of antigenic peptides to the endoplasmic reticulum: therapeutic potential and insights into TAP-dependent antigen processing" 1998 J Immunotherapy 21:127-31

A27

Calvert et al., "Fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus induce neutralizing antibodies and reduce viremia in chickens" J. of Virol 67:3069-3076, 1993

A28

Carroll et al., "Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen" 1998 J. Natl. Cancer Inst. 90(24):1881-1887


A29

"Two bright new faces in gene therapy" Nature Biotechnology 1996 14; 556

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1549
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

078883/0120

SERIAL NO.

09/533,798

INFORMATION DISCLOSURE CITATION

APPLICANT

Miles William CARROLL et al.

FILING DATE

3/24/2000

GROUP ART UNIT

1643

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

no	A30	Pleken et al., "Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes" 1991 Science 253:314-317
	A31	Parker et al., "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains" 1994 J. Immunol. 152:163-175
mp	A32	Fu et al., "An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope" 1998 J. Virol 72:1469-81
	A33	Schodel et al., "hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety" 1996 Intervirology 39:104-10
	A34	Wolff and Trubetskoy, "The cambrian period of nonviral gene delivery" 1998 nature Biotechnology 16:421-423
	A35	Taylor et al., "Biological and immunogenic properties of a canarypox-vaccines recombinant, ALVAC-RG (vCP65) in non-avian species" 1995 Vaccine 13:539-549
	A36	Stannard et al., "Evidence for incomplete replication of a penguin poxvirus in cells of mammalian origin" J. Gen. Virol. 1998 79:1637-46
	A37	Mackett et al., "Vaccinia virus: a selectable eukaryotic cloning and expression vector 1982 PNAS 79: 7415-7419
	A38	Upton et al., "Identification and nucleotide sequence of the thymidine kinase gene of Shope fibroma virus" J. Virology 60:920, 1986
	A39	Boyle et al., "Fowlpox virus thymidine kinase: nucleotide sequence and relationships to other thymidine kinases" Virology 156:355-365, 1987
	A40	Lewis et al., "Human immunodeficiency virus infection of cells arrested in the cell cycle" 1992 EMBO J 11:3053-3058
✓	A41	Lewis and Emerman "Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus" 1994 J. Virol. 68:510-516
no	A42	Mackett et al., "General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes" 1984, J. Virol. 49:857-864

EXAMINER

Marianne Doherty

DATE CONSIDERED

10/7/07

- EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

MAY 13 2004

Sheet 4 of 6

Form PTO-1519
(MODIFIED)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

078883/0120

SERIAL NO.

09/533,798

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT

Miles William CARROLL et al.

FILING DATE

3/24/2000

GROUP ART UNIT

1543 / 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

msd	A43	Hruby et al, "Fine structure analysis and nucleotide sequence of the vaccinia virus thymidine kinase gene"
		PNAS 80:3411-3415, 1983
	A44	Lytvyn et al, "Comparison of the thymidine dinase genes from three entomopoxiruses" J. Gen Virol
		73:3235-3240 1992
	A45	Smith et al., "Vaccinia virus immune evasion" 1997, Immunol Rev. 159:137-154
	A46	Jenkins et al, "Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus"
		AIDS Research and Human Retroviruses 7:991-998, 1991
	A47	Taylor et al, "Recombinant fowlpox virus inducing protective immunity in non-avian species" Vaccine 6:497-
		503, 1988
	A48	Sphener et al and Boursnell et al , "Insertion of the fusion gene from newcastle disease virus into a non-
		essential region in the terminal repeats of fowlpox virus and demonstration of protective immunity induced by
		The recombinant" 1990 J. Gen. Virol. 71:621-628
	A49	Nakano et al, "Molecular genetics of vaccinia virus: demonstration of marker rescue" Proc. Natl. Acad. Sci.
		USA 79, 1593-1596, 1982
	A50	Chakrabarti et al., "Vaccinia virus expression vector: coexpression of β -galactosidase provides visual
		screening of Recombinant virus plaques" Mol. Cell. Biol. 3403-3409, 1985
	A51	Wigler et al, "Transformation of mammalian cells with genes from procaryotes and eucaryotes" Cell 777-785,
		1979
	A52	Graessmann et al, "Microinjection of tissue culture cells" Meth. Enzymology 101, 482-492, 1983
	A53	Franke et al, "Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia
		virus recombinants" Mol Cell biol 1918-1924, 1985
msd	A54	Altenburger, W., Suter, C.P. and Altenburger J., "Partial deletion of the human host range gene in the
		attenuated vaccinia virus MVA" 1989 Arch. Virol. 105, 15-27


EXAMINER

Maurine D.


DATE CONSIDERED

7/10/07

- EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 078883/0120		SERIAL NO. 097533,798	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Miles William CARROLL et al.			
				FILING DATE 3/24/2000		GROUP ART UNIT 1643	
				1644			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
MO	A55	Neumann et al., "Gene transfer into mouse lyoma cell by electroporation in high electric fields" EMBO J. 1, 841-845, 1982					
MO	A56	Schaffner, "Direct transfer of cloned genes form bacteria to mammalian cells" Proc. Natl. Acad. Sci. USA 77,2163-2167, 1980					
	A57	Nestle FO et al, "Vaccinatio of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells" Nat. Med. 1998 Mar;4(3):328-32					
	A58	Altschul et al, "Issues in searching molecular sequence database" 1994 Nature Genetics 6:119-129.					
	A59	Carroll & Moss, "Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line", 1997 Virology 238:198-211					
MO	A60	Kim CJ et al., "Dendritic cell infected with poxviruses encoding Mart-1/melan a sensitive T Lymphocytes in vitro" J. Immunother, 1997 Jul;20(4):276-86					
	A61	Schneider et al., "enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara" 1998 Nat Med 4:397-402					
MO	A62	Chakrabarti et al, "Compact, synthetic, vaccinia virus early/late promoter for protein expression" 1997 Biotechniques 23:1094-1097					
MO	A63	Wyatt et al., "Development of replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model" 1996 Vaccine 14:1451-1458					
MO	A64	Sutter et al, "A recombinant vector derived from the host range-restricted and highly attenuated MVA strain Of vaccinia virus stimulates protective immunity in mice to Influenza virus", 1994 Vaccine 12:1032-1040					
MO	A65	Carroll and Moss "E. coli β -glucuronidase (GUS) as a marker for recombinant vaccinia viruses" 1995 Biotechniques 19:352-355					
MO	A66	Hirsch et al., "Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara" 1996 J. Virol 70:3741-3752					
EXAMINER 				DATE CONSIDERED 7/16/02			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 078883/0120	SERIAL NO. 097533, 798 <i>10/7/94/176</i>
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Miles William CARROLL et al.	
				FILING DATE 3/24/2000	GROUP ART UNIT 1643 <i>1644</i>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
<i>MO</i>	A67	Sutter and Moss, "Nonreplicating vaccinia vector efficiently expresses recombinant genes" 1992 Proc. Natl. Acad Sci USA 89:10847-10851			
<i>MO</i>	A68	Bronte et al., "Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine" 1997, Proc. Natl Acad Sci USA 94(7):3183-3188			
<i>MO</i>	A69	Wyatt et al., "Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells" 1995 Virology 210:202-205			
<i>MO</i>	A70	Carroll et al., "Highly attenuated modified-vaccinia-virus Ankara (MVA) as an effective recombinant vector: a Murine tumor model" 1997 Vaccine, 15:387-394			
<i>MO</i>	A71	Sutter et al., "Non-replication vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase" 1995 FEBS lett. 371:9-12			
<i>MO</i>	A72	Overwijk et al., "gp100/pmel 17 is a murine tumor rejection antigen induction of "Self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand", (1998) J. Exp. Med. 188: 277-286			
<i>MO</i>	A73	Hole N, and Stern PL, "Isolation and characterization of 5T4, a tumor-associated antigen", (1990) Int. J. Cancer 45(1): 179-184			
EXAMINER <i>Manir</i> DATE CONSIDERED <i>7/10/07</i>					
<ul style="list-style-type: none"> EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant. 					

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE		ATTY. DOCKET NO.		SERIAL NO.	
(MODIFIED)		PATENT AND TRADEMARK OFFICE		078883/0120		09/533,798 10/7/04	
MAY 13 2004 INFORMATION DISCLOSURE CITATION		Date Submitted to PTO: September 6, 2000		APPLICANT		Miles William CARROLL and Kevin Alan MYERS	
				FILING DATE		GROUP ART UNIT	
				March 24, 2000		1643 1644	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	A1	EP-A-0198328	04/02/88	Europe			
	A2	EP-A-0110385	11/29/83	Europe			
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
EXAMINER				DATE CONSIDERED			
				7/10/07			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							